BioNTech SE

BioNTech’s Q1 2026 report shows a shrinking vaccine revenue but new oncology trials and a manufacturing shift, positioning the firm for future growth as it pivots from vaccines to cancer‑therapeutics.

BioNTech’s Phase‑2 results for Trastuzumab Pamirtecan show a 47.9 % ORR and 8‑month PFS in HER2‑positive endometrial cancer, surpassing chemo and boosting stock outlook.

BioNTech’s trastuzumab pamirtecan shows 48% response in HER2‑positive recurrent endometrial cancer, while a new Boehringer partnership targets small‑cell lung cancer, and a €1.9 bn court win boosts its oncology pivot.

BioNTech pivots from COVID vaccine sales to a cancer‑focused future: closes costly Singapore plant, keeps profits in‑house, expands oncology board, and secures legal funding for new therapies.

BioNTech’s latest governance overhaul, 2025 revenue growth and cautious analyst optimism signal a post‑pandemic pivot toward oncology and vaccine innovation.

BioNTech’s co‑founders exit sparks a leadership vacuum and new mRNA‑focused spin‑off, weighing on stock price while the oncology pipeline pushes future growth.

BioNTech’s founders plan to leave and launch a new mRNA firm, yet shares stay near $90 and analysts keep buy ratings—what this means for investors.

BioNTech’s 2025 earnings fall short, posting a sharp operating loss, but a robust cash reserve and a future‑focused pipeline aim to revive growth amid co‑founder exit.

BioNTech’s 2025 earnings and a patent lawsuit vs. Moderna create a volatile mix, pushing the biotech stock below key support and sparking short‑selling interest.

BioNTech’s pivot to oncology, a high‑profile lawsuit against Moderna and new leadership reshuffle signal a bold but risky strategy shift—investors weigh potential growth against looming legal and financial uncertainty.